Korro Bio raised $91.5 million to run its platform of single-base RNA edits to treat a range of diseases. The Cambridge based biotech will use the cash haul toward getting its preclinical program into the clinic, while also “establishing a…
Escient Pharmaceuticals launched today with the completion of a $40 million Series A financing to advance first-in-class G Protein-Coupled Receptor (GPCR)-targeted drugs to address serious, unserved medical needs across a broad range of therapeutic indications. Focused on unleashing the therapeutic…
LyGenesis, Inc., a biotechnology company developing innovative technology for organ regeneration, announced today that they have raised $3 million in Series A financing from Juvenescence, Ltd. LyGenesis’ technology uses lymph nodes as bioreactors to regrow functioning organs within a patient’s…
Wellist, the leading provider of Integrated Patient Experience Solutions, announced today that it had raised $10 million in Series A funding. The round was led by Summation Health Ventures, a strategic healthcare investment fund affiliated with MemorialCare Health System and Cedars-Sinai…
